Floatz logo

Cediranib

Aggressive NK-cell Leukemia

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Aggressive NK-cell Leukemia cohort.

Asset / SponsorPhaseRating
Tas-102
National Cancer Institute (NCI)
Phase 1CC
mk-2206
National Cancer Institute (NCI)
Phase 1CC
su011248
National Cancer Institute (NCI)
Phase 1CC
Fludarabine
Fred Hutchinson Cancer Center
N/AD
Monomethyl Fumarate
Fred Hutchinson Cancer Center
N/AD
CYCLOSPORIN A
Fred Hutchinson Cancer Center
N/AD

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →